Evidence map›Paper›PMID 30900382›Full record

ArticleCancer medicine2019

Study of diffusion-weighted magnetic resonance imaging in the evaluation of the response to AAV2-VEGF-Trap neoadjuvant treatment in a triple-negative breast cancer animal model.

Jianhua Li, Pengjin Zhu, Lei Wang, Li Yang, Liqun Zou, Fabao Gao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jianhua LiThe First Department of Oncology, West China Hospital, Sichuan University, Chengdu, China.
Pengjin ZhuThe First Department of Oncology, West China Hospital, Sichuan University, Chengdu, China.
Lei WangDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Li YangDepartment of State/National Key Laboratory of Biotherapy, Sichuan University, Chengdu, China.
Liqun ZouThe First Department of Oncology, West China Hospital, Sichuan University, Chengdu, China.
Fabao GaoThe First Department of Oncology, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0003-2257-3275
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveEvaluation of the efficacy of adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap (AAV2-VEGF-Trap) alone or combination with paclitaxel in a mouse model of triple-negative breast cancer (TNBC) using diffusion-weighted magnetic resonance imaging (DW-MRI) and in vivo fluorescence imaging. MATERIALS AND

methodsXenografted TNBC tumors were established by subcutaneous injection of MDA-MB-231 cells into nude mice. Tumors were treated with AAV2-VEGF-Trap, paclitaxel, AAV2-VEGF-Trap combined with paclitaxel and control. A 7.0-Tesla magnetic resonance (MR) was used to obtain the apparent diffusion coefficient (ADC) values and ΔADC values. In vivo fluorescence imaging coupled with the optical imaging probe AngioSense680 EX was acquired to obtain average luminous intensity values. Immunohistochemical staining of tumor Ki-67 and vascular endothelial cell marker antigen (CD31) were used to evaluate the effects on tumor proliferation and angiogenesis.

resultsThe combination of AAV2-VEGF-Trap with paclitaxel exhibited greater tumor growth inhibition compared with the other groups. The ADC values in the paclitaxel group and the AAV2-VEGF-Trap in combination with paclitaxel group were significant greater compared with the control group, and the ΔADC values of all treatment groups were significantly increased compared with the control group on the 14th day after administration. Decreased microvessel density and luminous intensity in the treatment groups that contain AAV2-VEGF-Trap were observed. Reduced proliferation activity was noted in groups that contained paclitaxel.

conclusionAAV2-VEGF-Trap inhibits TNBC growth though inhibiting tumor neovascularization with a single intravenous injection, and AAV2-VEGF-Trap exhibits a synergistic effect when used in combination with paclitaxel for TNBC neoadjuvant therapy. In vivo fluorescence imaging can detect the anti-angiogenesis effect of AAV2-VEGF-Trap early and noninvasively. DW-MRI can longitudinally monitor the neoadjuvant efficacy of TNBC.

Indexed as

Diffusion Magnetic Resonance ImagingAnimalsCell Line, TumorDependovirusDisease Models, AnimalGenetic VectorsHumansImmunohistochemistryMiceMolecular ImagingNeoadjuvant TherapyNeovascularization, PathologicParvovirinaeTriple Negative Breast NeoplasmsVascular Endothelial Growth Factor AXenograft Model Antitumor AssaysVascular Endothelial Growth Factor AAAV2-VEGF-Trapangiogenesisapparent diffusion coefficientdiffusion-weighted magnetic resonance imagingin vivo fluorescence imagingtriple-negative breast cancerΔ ADC

Identifiers

PMID30900382
PMCPMC6488150
OpenAlexW2923832166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.